KRAS and familial pancreatic carcinoma: Mutations of the oncoprotein KRAS are very common in pancreatic cancer, and therefore there has always been a great deal of interest in targeting the MAPK pathway in the treatment of pancreatic cancer, but while there have been some promising pre-clinical results, KRAS inhibitors have shown to be relatively ineffective at treating pancreatic cancer in humans.